BIM
CTMX icon

BlackRock Investment Management’s CytomX Therapeutics CTMX Stock Holding History

BlackRock Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$847K Buy
77,074
+495
+0.6% +$6K ﹤0.01% 2791
2016
Q3 		$1.2M Sell
76,579
-131
-0.2% -$1.58K ﹤0.01% 2546
2016
Q2 		$784K Buy
76,710
+49,279
+180% +$562K ﹤0.01% 2799
2016
Q1 		$354K Buy
27,431
+664
+2% +$9.22K ﹤0.01% 3023
2015
Q4 		$559K Buy
+26,767
New +$424K ﹤0.01% 2958

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock Investment Management's CTMX Position: Q4 2016 in Review

BlackRock Investment Management increased its CytomX Therapeutics (CTMX) stake by 0.65% in Q4 2016, buying an estimated $6K and bringing the position to 77,074 shares worth $847K. The position accounts for ﹤0.01% of the portfolio, ranked #2791.

BlackRock Investment Management first reported a position in CTMX in Q4 2015 and has held it in 5 quarters since. The position peaked at $1.2M in Q3 2016. 68 funds tracked by Wall St. Rank hold CTMX as of Q4 2016.

  • BlackRock Investment Management held 77,074 shares of CytomX Therapeutics worth $847K as of Q4 2016.
  • BlackRock Investment Management bought 495 CytomX Therapeutics shares in Q4 2016, an estimated $6K.
  • CytomX Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2791 holding.
  • BlackRock Investment Management first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 5 quarters since.
  • BlackRock Investment Management's CytomX Therapeutics position peaked at $1.2M in Q3 2016.
  • 68 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.